Announcement of the Sumitomo Pharma's Construction of the Technical Transformation Project of New Pharmaceutical Diagnostic Drugs and the Completion Date and Commissioning Start-End Date of Supporting Environmental Protection Facilities
2022-03-14
According to the Interim measures for inspection and acceptance of environmental protection of the completed constructions and other relevant regulations, the company discloses information about the completion date and commissioning start and end dates of the supporting environmental protection facilities of the technical renovation project of Sumitomo Pharma (Suzhou) Co., Ltd.(Suzhou) Co., Ltd.on the development of new diagnostic and therapeutic drugs, informing the public who may be affected by the construction work. The company understands the public attitude and welcomes suggestions from the public regarding this project through appropriate measures.
Project Name: Technical renovation project of Sumitomo Pharma (Suzhou) Co., Ltd.(Suzhou) Co., Ltd. on the development of novel diagnostic and therapeutic drugs
Owner: Sumitomo Pharma (Suzhou) Co., Ltd.(Suzhou) Co., Ltd.
Address: 115 Qingqiu Street, Suzhou Industrial Park
Construction Overview: The project investment is RMB3.2 million and the investment towards environmental protection is RMB100,000. Business scope: The drugs that have obtained patent rights or administrative protection for development and production in China are novel anti-cancer drugs, novel cardiovascular drugs, anti-allergic drugs, other novel drugs, and diagnostic markers recognized by the Chinese government. Further, Sumitomo Pharma (Suzhou) Co., Ltd. (Suzhou) Co., Ltd.offers sales of products manufactured by the company, consulting services regarding medical products, and related businesses. This construction is for the technical renovation projects on the development of novel therapeutic drugs and diagnostic kits, including the technological development of the production process of psychoneurotic drug tandospirone citrate tablets and the technological development of the testing method for the psychoneurotic drugs, lurasidone hydrochloride tablets and blonanserin tablets. The samples generated from the production process and testing methods of technological development are treated as waste products and are not intended for sale. The tandospirone citrate tablets (Sediel® tablets) project does not have approval for the production, and therefore, this agreement only involves the laboratory investigation, not production.
1. Sewage pollution and treatment measures
The production of wastewater from this project includes a small amount of water generated from the washing of the laboratory vessels using tap water, which is mixed with other wastewater and domestic sewage from the existing project and discharged directly into the first wastewater treatment plant in the park for centralized treatment.
2. Exhaust gas pollution and treatment measures
A small amount of volatile organic solvents is used in the laboratory for this project. A few solvents evaporate and escape during the experimental process, and the generated volatile organic compounds are collected through the fume hood and treated with activated carbon before being discharged into a 15 m high P1 exhaust. The portion of the volatile gas that cannot be completely captured is discharged by strengthened ventilation and other measures.
3. Noise pollution and treatment measures
The project has no new production equipment, based on existing production equipment. The primary noise comes from the equipped fan. Noise generation and transmission are reduced by sound insulation, vibration damping, and other processes.
4. Solid waste pollution and treatment measures
The solid wastes produced from this project are hazardous [scrapped drug (S1), waste wipes (S2), waste liquid containing organic solvents (S3), waste culture medium and cleaning solution (S4), waste packaging materials (S5), waste activated carbon (S6), and dust (S7)] and domestic wastes.
1. Completion date: 30 November 2016
2. Commissioning start and end dates: From 1 December 2016 to 1 October 2017
Residents, organizations, and other members of the public who are concerned about this project or reside within the impacted area of the project.
The public can send letters and emails to the designated address on the announcement to express their opinions regarding the project. Please provide detailed contact information while expressing your opinion and concern, and the construction unit will address the public's concern regarding the construction project and take remedial measures.
Contact: 计刚
Tel: 13862671071
E-mail: jig@sumitomo-pharma.com.cn
